Mologen (MGN)

Business description

Mologen is a German biotech company developing cancer immunotherapies. The lead product is lefitolimod (MGN1703) for metastatic colorectal cancer maintenance, SCLC and HIV. Development of MGN1601, a therapeutic renal cell vaccine, would be reinitiated on successful out-licensing of lefitolimod.

'Next Level' on track

QuickView | Pharmaceutical & healthcare | 09/11/2016

Mologen are focused on the development and commercialisation of lead candidate lefitolimod (oncology and HIV) and the next-generation molecules EnanDIM (TLR9 agonist). Partnering opportunities for lefitolimod are being actively sought. We anticipate Phase II IMPULSE (SCLC) data in early/mid-2017 and initial Phase III IMPALA (mCRC) data 24 months after final patient recruitment to drive the shares. Following the capital raise we now value Mologen at €251m (€7.39/share).

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.€79.7m
Last close€2.305
High / Low (52 weeks)€4.6 / €1.9
Stock market listingDE
Forecast net cash (€m)0.2
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual(2)(19.7)2.5
Relative *(2.6)(20.8)(10.3)

* % Relative to local index

Company news